Literature DB >> 21813548

Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis.

N B Klarenbeek1, R Koevoets, D M F M van der Heijde, A H Gerards, S Ten Wolde, P J S M Kerstens, T W J Huizinga, B A C Dijkmans, C F Allaart.   

Abstract

OBJECTIVE: To compare nine disease activity indices and the new American College of Rheumatology (ACR)/European League against Rheumatism (EULAR) remission criteria in rheumatoid arthritis (RA) and to relate these to physical function and joint damage progression.
METHODS: Five-year data from the BeSt study were used, a randomised clinical trial comparing four treatment strategies in 508 patients with recent-onset RA. Every three months disease activity was assessed with nine indices (Disease Activity Score (DAS), DAS-C reactive proteine (DAS-CRP), Disease Activity Score in 28 joints (DAS-28), DAS28-CRP, Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI) and three DAS versions with adjusted tender joint scores) and categorized into remission, low, moderate and high disease activity (LDA, MDA, HDA). In addition, the recent ACR/EULAR clinical trial and practice remission was assessed 3-monthly with 28 and 68/66 joint counts. For each index, Generalized Estimating Equations analyses were performed to relate disease activity levels and the absence/presence of remission to 3-monthly assessments of physical functioning and annual radiological progression.
RESULTS: From the composite indices, CDAI and SDAI were the most stringent definitions of remission and classified more patients as LDA. DAS28 and DAS28-CRP had the highest proportions of remission and MDA and a smaller proportion of LDA. ACR/EULAR remission percentages were comparable to CDAI/SDAI: remission percentages. The variant including CRP and 68/66 joint counts was the most stringent. For all indices, higher levels of disease activity were associated with decreased physical functioning and more radiological damage progression. Despite differences in classification between the indices, no major differences in relation to the two outcomes were observed.
CONCLUSION: The associations of nine composite indices and ACR/EULAR remission criteria with functional status and joint damage progression showed high accordance, whereas the proportions of patients classified in the disease activity levels differed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21813548     DOI: 10.1136/ard.2010.149260

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  30 in total

1.  Factors influencing ultrasonographic remission in patients with rheumatoid arthritis.

Authors:  Halil Harman; Ibrahim Tekeoğlu; Nedim Kaban; Sibel Harman
Journal:  Rheumatol Int       Date:  2014-11-16       Impact factor: 2.631

Review 2.  RA in 2011: Advances in diagnosis, treatment and definition of remission.

Authors:  Gerd R Burmester
Journal:  Nat Rev Rheumatol       Date:  2012-01-10       Impact factor: 20.543

3.  Rheumatoid arthritis: defining remission in patients with RA in clinical practice.

Authors:  Rene Westhovens; Patrick Verschueren
Journal:  Nat Rev Rheumatol       Date:  2012-07-03       Impact factor: 20.543

4.  [Early and advanced rheumatoid arthritis. Diagnosis and state of the art therapy strategy].

Authors:  J Wollenhaupt; K Krüger
Journal:  Z Rheumatol       Date:  2012-01       Impact factor: 1.372

5.  Revising DAS28 scores for remission in rheumatoid arthritis.

Authors:  Claire Sheehy; Verity Evans; Heather Hasthorpe; Chetan Mukhtyar
Journal:  Clin Rheumatol       Date:  2014-01-03       Impact factor: 2.980

Review 6.  Rheumatoid arthritis--early diagnosis and disease management.

Authors:  Matthias Schneider; Klaus Krüger
Journal:  Dtsch Arztebl Int       Date:  2013-07-08       Impact factor: 5.594

Review 7.  Maximizing early treatment with biologics in patients with rheumatoid arthritis: the ultimate breakthrough in joints preservation.

Authors:  Andra Balanescu; Piotr Wiland
Journal:  Rheumatol Int       Date:  2013-01-09       Impact factor: 2.631

8.  Comparative effectiveness of adalimumab and etanercept for rheumatoid arthritis in the Brazilian Public Health System.

Authors:  Jéssica Barreto Ribeiro Dos Santos; Alessandra Maciel Almeida; Francisco de Assis Acurcio; Haliton Alves de Oliveira Junior; Adriana Maria Kakehasi; Augusto Afonso Guerra Junior; Marion Bennie; Brian Godman; Juliana Alvares
Journal:  J Comp Eff Res       Date:  2016-09-19       Impact factor: 1.744

9.  Validation of ACR/EULAR definition of remission in rheumatoid arthritis from RA practice: the ESPOIR cohort.

Authors:  Bin Zhang; Bernard Combe; Nathalie Rincheval; David T Felson
Journal:  Arthritis Res Ther       Date:  2012-06-29       Impact factor: 5.156

10.  An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression.

Authors:  Annette H M van der Helm-van Mil; Rachel Knevel; Guy Cavet; Tom W J Huizinga; Douglas J Haney
Journal:  Rheumatology (Oxford)       Date:  2013-01-03       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.